Guggenheim analyst Seamus Fernandez started Merck with a Buy rating and $84 price target, citing the sales and EPS upside he sees as Keytruda growth expands in the U.S. and globally. He also sees some partner products, such as Lynparza and Lenvima, along with the company’s pipeline as being underappreciated, Fernandez tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.